1. Scrip
  2. >>Business

Vildagliptin Prices Fall By Over 70% In India Post Patent Expiry

Novartis Sells Vildagliptin Brand To USV, Cipla Explores Talks

 
• By Vibha Ravi

Vildagliptin formulation prices fall by over 70% following the expiry of a patent held by Novartis in India. The innovator, meanwhile, is cashing in on co-marketing agreements with Indian partners like USV and Cipla

Wrestlers
Gliptins Price War Set To Intensify • Source: Shutterstock

Novartis AG has cashed out on two of its four licensed brands for vildagliptin in India, after a patent on the drug expired 9 December. Prices of vildagliptin and its combination are expected to drop sharply hereon, with one firm Panacea Biotec Ltd.'s product debuting at a discount of over 70% to current prices.

Novartis markets vildagliptin, an oral anti-hyperglycemic agent, as Galvus and vildagliptin in combination with metformin hydrochloride as Galvus Met. It...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By Mandy Jackson

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

Wave of Biopharma Licensing Deals in India: ‘The Model Is Working’

 
• By Anju Ghangurde

From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.